New delivery systems may revive potential of peptide drugs

01/14/2005 |

New therapeutic approaches, plus the potential of the drugs themselves, may mean a renaissance in peptide drugs, according to a new report. Approval of new peptide-based drug products, such as Roche's HIV treatment Fuzeon, is increasing interest among pharmaceutical companies. In Europe, as many as six peptide-based products are on the market, with 100 in the clinical stage and 150 in advanced preclinical phases.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA